Objective: The aim of this study was to analyze the physical activity level, using two tools, and the functional capacity of children and adolescents with asthma and with different levels of disease control, and to compare them to those of individuals without asthma. Methods: Cross-sectional study with children and adolescents with (asthma group, AG) and without asthma (WAG), aged from 7 to 17 years. All participants performed the six-minute walk test (6MWT), the Glittre Activities of Daily Living test (Glittre-ADL), the International Physical Activity Questionnaire (IPAQ), and daily record of steps on a pedometer. Results: The study included 145 individuals with asthma and 173 individuals without asthma. The WAG walked a greater distance in the 6MWT and performed the Glittre-ADL in less time than the AG. Individuals with uncontrolled, partially controlled, and controlled asthma presented the same functional capacity. A difference was observed in the IPAQ classification, with 13.9% of participants from the WAG being sedentary, compared with 26.2% in the AG. The mean quantity of steps measured by the pedometer was higher in the WAG. Conclusion: There was a difference in the performance of individuals with and without asthma in the physical activity and functional capacity tests. The AG presented worse performance in the physical activity tests and, regardless of the level of asthma control, presented worse functional capacity. (C) 2020 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.
Purpose: This study aimed to investigate the association between asthma severity, lung function and serum levels of cytokines associated with T‐helper type 2 (T2) and non‐T2 responses in children and adolescents. Methods: We conducted a cross‐sectional study and recruited children and adolescents (7–17 years old) with asthma. Asthma severity was classified by daily corticosteroid dosage and pulmonary function, while asthma control was assessed using the Asthma Control Test and the Child Asthma Control Test. Spirometry, blood collection for cytokine analysis (IL‐4, IL‐5, IL‐10, IL‐13, IL‐17, IFNγ, TNF‐α), and induced sputum collection for cellularity evaluation were performed. Results: A total of 80 participants were included, with a mean age of 11.9 years, and 60% were male. Severe asthma was observed in 17.5%, and 15% had uncontrolled asthma. No differences in sputum cellularity were found ( p = 0.509). Cytokine levels of TNF‐α ( p = 0.043) and IL‐5 ( p = 0.010) differed by asthma severity. Negative correlations were observed between cytokines (IL‐4, IL‐5, IL‐10, IL‐17) and spirometric parameters. IL‐17 ( p = 0.001) and IL‐5 ( p = 0.045) levels varied with airway obstruction, and IL‐17 levels differed with bronchodilator response in FEV1 ( p = 0.041). Conclusions: Our findings highlight the heterogeneity of immune responses in childhood asthma. Cytokines from both T2 and non‐T2 pathways were associated with lung function impairment, underscoring the interplay of diverse immune responses in the complexity of asthma pathophysiology.
Introduction: Premature infants are at increased risk of developing chronic respiratory diseases, predisposing them to severe infections, such as those caused by respiratory syncytial virus (RSV). Palivizumab reduces the severity of RSV infections in high‐risk children; however, its relationship with asthma development in premature infants remains unclear. Objective: This systematic review with meta‐analysis aimed to review the literature and assess whether prophylaxis with palivizumab protects premature infants without congenital heart disease from developing asthma. Results: In total, 14 studies met the inclusion criteria, assessing 1,364,238 children; of these, 9232 received palivizumab. No significant difference in the chance of developing asthma between the groups (odds ratio (OR) of 0.84, 95% CI [0.62–1.13], p = 0.1968). Heterogeneity between studies was I ² = 35.6%. Subgroup analysis for children with a family history of atopy showed no significant reduction in asthma risk (OR 0.78, 95% CI: 0.40–1.55, p = 0.3390). Sensitivity analysis confirmed result robustness. IgE levels were similar between the groups (standardized mean difference [SMD] −0.03 [95% CI: −0.30; 0.23], p = 0.8088). Children who received palivizumab were diagnosed younger (SMD −0.24 [95% CI: −0.38; −0.09], p = 0.0014), with lower gestational age (MD −0.75 [95% CI: −1.61; 0.12], p = 0.0915). Conclusions: Palivizumab prophylaxis does not reduce asthma risk in premature children without congenital heart disease. Its primary benefit lies in preventing severe RSV infections, with no direct impact on asthma developing.
Context: Vitamin D may modulate the inflammatory processes involved in asthma. Objective: To synthesize evidence on the association between serum 25‐hydroxyvitamin D levels and asthma control, severity, pulmonary function, and inflammatory markers in children and adolescents. Data Sources: MEDLINE PubMed, BIREME, EBSCOhost, Scopus, Web of Science, EMBASE, Cochrane Library, and ProQuest until May 2025. Study Selection: Eligible studies enrolled participants aged 2–18 years with clinically diagnosed asthma and evaluated serum vitamin D levels in relation to asthma severity and/or control and pulmonary function parameters or type 2 inflammatory biomarkers. We included observational and randomized studies. Data Extraction: The risk of bias for studies was assessed. Random‐effects models estimated pooled outcomes. The heterogeneity was assessed using Cochran's Q and the I² statistic. Results: Forty‐one studies (7780 participants) were included; 25 contributed to meta‐analyses. Children with asthma had significantly lower serum 25(OH)D levels than healthy controls (mean difference −4.89 ng/mL; 95% CI −7.38 to −2.40; p < 0.001). Severe asthma was associated with lower vitamin D compared with mild disease (−4.21 ng/mL; 95% CI −6.43 to −1.98; p = 0.0002). No significant difference was observed between controlled and uncontrolled asthma. Correlations with pulmonary function were weak and non‐significant (FEV₁ r = 0.18; p = 0.08). Vitamin D showed a moderate inverse association with total IgE ( r = −0.37; p = 0.02), but not with eosinophil counts or IL‐10. Heterogeneity was high across analyses. Conclusions: Children with asthma exhibit lower serum vitamin D levels compared with healthy peers, and these levels are inversely associated with asthma severity and total IgE. No consistent associations were observed with pulmonary function or asthma control. Further research is needed to determine whether correcting vitamin D deficiency can improve clinical and immunologic outcomes in pediatric asthma.
Vitamin D may modulate the inflammatory processes involved in asthma. To synthesize evidence on the association between serum 25-hydroxyvitamin D levels and asthma control, severity, pulmonary function, and inflammatory markers in children and adolescents. MEDLINE PubMed, BIREME, EBSCOhost, Scopus, Web of Science, EMBASE, Cochrane Library, and ProQuest until May 2025. Eligible studies enrolled participants aged 2-18 years with clinically diagnosed asthma and evaluated serum vitamin D levels in relation to asthma severity and/or control and pulmonary function parameters or type 2 inflammatory biomarkers. We included observational and randomized studies. The risk of bias for studies was assessed. Random-effects models estimated pooled outcomes. The heterogeneity was assessed using Cochran's Q and the I² statistic. Forty-one studies (7780 participants) were included; 25 contributed to meta-analyses. Children with asthma had significantly lower serum 25(OH)D levels than healthy controls (mean difference -4.89 ng/mL; 95% CI -7.38 to -2.40; p < 0.001). Severe asthma was associated with lower vitamin D compared with mild disease (-4.21 ng/mL; 95% CI -6.43 to -1.98; p = 0.0002). No significant difference was observed between controlled and uncontrolled asthma. Correlations with pulmonary function were weak and non-significant (FEV₁ r = 0.18; p = 0.08). Vitamin D showed a moderate inverse association with total IgE (r = -0.37; p = 0.02), but not with eosinophil counts or IL-10. Heterogeneity was high across analyses. Children with asthma exhibit lower serum vitamin D levels compared with healthy peers, and these levels are inversely associated with asthma severity and total IgE. No consistent associations were observed with pulmonary function or asthma control. Further research is needed to determine whether correcting vitamin D deficiency can improve clinical and immunologic outcomes in pediatric asthma.